Recent evidence has shown a greater risk of dementia, in particular Alzheimer's disease (AD), in individuals using anticholinergic medications regularly. These drugs are widely used by older adults to treat bladder dysfunction, mood, and pain, and many of them are available without prescription. Since these drugs are often used to treat both motor symptoms and non-motor symptoms in patients with Parkinson's Disease (PD), there is concern for increased risk of dementia. Contrary to expectations, a study in the current issue of theJournal of Parkinson's Disease determined that the cognitive performance of PD patients taking anticholinergic medications did not differ from those who did not.
Principal investigator David J. Burn, Director of the Institute of Neuroscience and Professor of Movement Disorder Neurology at Newcastle University, UK, explained, "This is the first study to explore an association between anticholinergic burden and mild cognitive impairment (MCI) in PD participants, and is timely given recent research demonstrating cumulative anticholinergic burden and risk of AD in the general population. Our assessment will help determine whether patients prescribed medication with anticholinergic activity are more likely to develop dementia, and hence allow early targeted intervention to reduce future risk."
Using data from the Incidence of Cognitive Impairment in Cohorts with Longitudinal Evaluation -- Parkinson's Disease study (ICICLE-PD), a twin center longitudinal observational study of the anatomical, biochemical, and genotypic mechanisms underlying the evolution of persons developing dementia (PDD), the investigators studied 195 PD patients and 84 control patients. The PD patients' detailed medication history, including over-the-counter drugs, was evaluated according to the Anticholinergic Drug Scale (ADS). Each drug was classified on a scale from 0 to 3 according to no (0), mild (1), moderate (2) or high (3) anticholinergic activity. Total usage from baseline to 18-month follow up was used to produce a total burden score. Those with ADS scores greater than or equal to 1 were in the PD+ADS group while those with ADS scores equal to 0 were designated PD-ADS.
Comparison of the PD+ADS (n = 83) and PD-ADS (n = 112) groups revealed no differences with respect to global cognition or assessments of attention, memory, and executive function at 18 months. The proportion of mild cognitive impairment (MCI) was similar in those with and without anticholinergic drug use. Although a greater proportion of PD subjects were taking anticholinergic medications, the total drug burden did not differ between the PD patients and controls.
The above post is reprinted from materials provided by University of Colorado Anschutz Medical Campus. Note: Materials may be edited for content and length.
Disclaimer: DoveMed is not responsible for the adapted accuracy of news releases posted to DoveMed by contributing universities and institutions.
Primary Resource:
Yarnall, A. J., Lawson, R. A., Duncan, G. W., Breen, D. P., Khoo, T. K., Brooks, D., ... & Burn, D. J. (2015). Anticholinergic Load: Is there a Cognitive Cost in Early Parkinson's Disease?. Journal of Parkinson's disease, 5(4), 743-747.
and connect with fellow professionals
At DoveMed, our utmost priority is your well-being. We are an online medical resource dedicated to providing you with accurate and up-to-date information on a wide range of medical topics. But we're more than just an information hub - we genuinely care about your health journey. That's why we offer a variety of products tailored for both healthcare consumers and professionals, because we believe in empowering everyone involved in the care process.
Our mission is to create a user-friendly healthcare technology portal that helps you make better decisions about your overall health and well-being. We understand that navigating the complexities of healthcare can be overwhelming, so we strive to be a reliable and compassionate companion on your path to wellness.
As an impartial and trusted online resource, we connect healthcare seekers, physicians, and hospitals in a marketplace that promotes a higher quality, easy-to-use healthcare experience. You can trust that our content is unbiased and impartial, as it is trusted by physicians, researchers, and university professors around the globe. Importantly, we are not influenced or owned by any pharmaceutical, medical, or media companies. At DoveMed, we are a group of passionate individuals who deeply care about improving health and wellness for people everywhere. Your well-being is at the heart of everything we do.
0 Comments
Please log in to post a comment.